Discovery, Characterization, & Advancement, of Novel Chemotypes of Potent & Selective Brain Penetrant & Peripherally Restricted NLRP3 Inhibitors

Time: 10:00 am
day: Day Two


Hear about the first study of Selnoflast in participants with early idiopathic PD; characterization of a new compound targeting NLRP3 inflammasome and innovative Ph1b design to test safety, pharmacokinetics and pharmacodynamics